Top 5 Global Neuroscience Pharma Companies: Core Products and Pipeline Analysis

Neuroscience (CNS) has long been regarded as one of the most challenging areas in the pharmaceutical industry, due to long development timelines, high failure rates, and complex disease mechanisms.

✨ In recent years, breakthroughs in Alzheimer’s disease (AD), multiple sclerosis (MS), and migraine therapies have accelerated innovation, prompting global neuroscience pharma companies to expand their CNS pipelines and develop innovative drugs.

As a global pharmaceutical distributor, DengYueMed reviews the top 5 global neuroscience pharma companies, along with their key products and pipeline strategies, to provide insights into industry trends and future directions.

Roche: Dual Engine in MS and Neurodegenerative Diseases

Roche has long maintained a leading position in the CNS pharma market, ranking first globally in neuroscience-related revenue.

Core Products

1. Ocrevus (ocrelizumab)
Ocrevus is a CD20-targeting monoclonal antibody that selectively depletes B cells, thereby reducing CNS inflammation and slowing disease progression in multiple sclerosis (MS).
It is approved for both relapsing and primary progressive MS, significantly reducing relapse rates and delaying disability progression, making it a cornerstone therapy in CNS drug development.

2. Evrysdi (risdiplam)
Evrysdi is an SMN2 splicing modifier that increases functional SMN protein production, addressing the underlying pathology of spinal muscular atrophy (SMA).
Its oral administration improves patient compliance and represents a shift toward long-term disease management in rare CNS diseases.

Pipeline

• Trontinemab (Phase III): brain shuttle technology enhancing blood-brain barrier penetration for AD
• Prasinezumab (Phase III): targeting alpha-synuclein in Parkinson’s disease
• Gene therapy collaboration with Sangamo Therapeutics

👉 Roche is transitioning from symptom control to disease-modifying therapies (DMTs), reinforcing its leadership among the top 5 global neuroscience pharma companies.

AbbVie: Comprehensive CNS Portfolio in Migraine and Psychiatry

AbbVie has positioned CNS as a key growth driver, becoming one of the top 5 global neuroscience pharma companies with a diversified product portfolio.

Core Products

1. Vraylar (cariprazine)
A dopamine D3/D2 receptor partial agonist with preferential D3 activity, Vraylar modulates mood and cognition, showing efficacy in schizophrenia, bipolar disorder, and adjunctive treatment of major depressive disorder.

2. Ubrelvy (ubrogepant) / Qulipta (atogepant)
Both target the CGRP pathway:

• Ubrelvy: CGRP receptor antagonist for acute migraine
• Qulipta: preventive therapy

These CNS drugs reduce neurogenic inflammation and vasodilation, marking a shift toward targeted migraine therapies. 🎯

3. Botox Therapeutic (onabotulinumtoxinA)
Inhibits acetylcholine release at neuromuscular junctions, reducing muscle contraction and pain signaling, widely used in chronic migraine prevention.

Pipeline

• Tavapadon (filed): selective D1/D5 agonist for Parkinson’s disease
• Darigabat (Phase II): GABA-A modulator for epilepsy
• ALIA-1758 (Phase I): bispecific antibody for AD
• Bretisilocin (Phase II): novel neuropsychiatric mechanism

👉 AbbVie has built a multi-pathway strategy across neurotransmitters, neuropeptides, and novel psychiatric mechanisms, enabling broad coverage of the CNS field.

Novartis: Growth Driven by Advanced Therapies

Novartis is one of the fastest-growing companies in the global CNS therapeutics space, driven by precision immunotherapy and gene therapy.

Core Products

1. Kesimpta (ofatumumab)
A fully human anti-CD20 monoclonal antibody administered via subcutaneous injection, enabling convenient at-home treatment.
It effectively reduces relapse rates and MRI lesions in MS, gaining rapid adoption in the CNS market.

2. Zolgensma (onasemnogene abeparvovec)
A gene therapy using an AAV vector to deliver a functional SMN1 gene, addressing the root cause of SMA.
Its one-time administration offers long-term benefits, representing a breakthrough in CNS disease treatment.

Pipeline

• RNA therapeutics platform
• Expanded gene therapy programs
• Early-stage projects in AD and SMA
• EDK060 and VHB937 targeting unmet CNS needs

👉 Novartis exemplifies the shift from chronic treatment to functional cures among the top 5 global neuroscience pharma companies.

Johnson & Johnson: Innovation in Difficult-to-Treat Psychiatric Disorders

Johnson & Johnson focuses on high unmet needs in psychiatric and neurological disorders.

Core Products

1. Spravato (esketamine)
An NMDA receptor antagonist that modulates glutamate signaling, enhancing synaptic plasticity.
It provides rapid antidepressant effects, addressing limitations of traditional therapies.

2. Caplyta (lumateperone)
A multi-modal agent acting on dopamine, serotonin, and glutamate systems, offering efficacy with a favorable metabolic profile.

Pipeline

• Seltorexant (Phase III): Orexin-2 receptor antagonist
• Posdinemab (Phase II): anti-Tau antibody
• Programs in anxiety, PD, and neuroinflammation

👉 The company is driving a shift toward neural network-based treatment approaches in CNS diseases.

Biogen: A CNS-Focused Pioneer

Biogen remains one of the most specialized players among the top 5 global neuroscience pharma companies, with deep expertise in CNS innovation.

Core Products

1. Spinraza (nusinersen)
An antisense oligonucleotide (ASO) therapy that modifies SMN2 splicing to increase SMN protein levels, pioneering RNA therapeutics in CNS diseases.

2. Tecfidera (dimethyl fumarate) / Vumerity (diroximel fumarate)
Activate the Nrf2 pathway, reducing oxidative stress and inflammation in MS.

3. Leqembi (lecanemab) (in collaboration with Eisai)
Targets soluble beta-amyloid to slow cognitive decline in early AD.

Pipeline

Biogen continues to expand in neurodegenerative and rare diseases, including ALS, AD, and RNA-based therapies.

👉 Biogen has played a key role in advancing RNA drugs and disease-modifying therapies across the top 5 global neuroscience pharma companies landscape.

Conclusion

The competitive landscape of neuroscience is increasingly defined by the top 5 global neuroscience pharma companies:

• Roche and AbbVie: strong scale and product portfolios
• Johnson & Johnson: differentiated mechanisms in psychiatry
• Biogen: deep CNS expertise and RNA platform
• Novartis: rapid growth driven by gene and RNA therapies

With continued advancements in monoclonal antibodies, gene therapy, and RNA therapeutics, CNS drug development is shifting from symptom management toward disease modification and potential cures.

As neuroscience innovation accelerates, global drug accessibility becomes increasingly important. As a global pharmaceutical distributor, DengYueMed remains committed to tracking cutting-edge CNS therapies and supporting partners with reliable supply and industry insights.

FAQ about Top 5 Global Neuroscience Pharma Companies